tbuckley/cabot-search huggingface dataset:
I-MOVE multicentre case–control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
Authors: Esther Kissling, Baltazar Nunes, Chris Robertson, Marta Valenciano, Annicka Reuss, Amparo Larrauri, Jean Marie Cohen, Beatrix Oroszi, Caterina Rizzo, Ausenda Machado, Daniela Pitigoi, Lisa Domegan, Iwona Paradowska-Stankiewicz, Udo Buchholz, Alin Gherasim, Isabelle Daviaud, Judit Krisztina Horváth, Antonino Bella, Emilia Lupulescu, Joan O´Donnell, Monika Korczyńska, Alain Moren
Journal: Eurosurveillance (2016)

Since the 2008/9 influenza season, the I-MOVE multicentre case–control study measures influenza vaccine effectiveness (VE) against medically-attended influenza-like-illness (ILI) laboratory confirmed as influenza. In 2011/12, European studies reported a decline in VE against influenza A(H3N2) within the season. Using combined I-MOVE data from 2010/11 to 2014/15 we studied the effects of time since vaccination on influenza type/subtype-specific VE. We modelled influenza type/subtype-specific VE by time since vaccination using a restricted cubic spline, controlling for potential confounders (age, sex, time of onset, chronic conditions). Over 10,000 ILI cases were included in each analysis of influenza A(H3N2), A(H1N1)pdm09 and B; with 4,759, 3,152 and 3,617 influenza positive cases respectively. VE against influenza A(H3N2) reached 50.6% (95% CI: 30.0–65.1) 38 days after vaccination, declined to 0% (95% CI: -18.1–15.2) from 111 days onwards. At day 54 VE against influenza A(H1N1)pdm09 reached 55.3% (95% CI: 37.9–67.9) and remained between this value and 50.3% (95% CI: 34.8–62.1) until season end. VE against influenza B declined from 70.7% (95% CI: 51.3–82.4) 44 days after vaccination to 21.4% (95% CI: -57.4–60.8) at season end. To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed.
TCTAP A-019 Immediate and Mid-Term Results of the Use of Antiembolic Mesh-Covered Stents ‘Mguard’ in Patients with Acute ST-Elevation Coronary Syndrome
Authors: Dzhamil Arif Ogly Asadov, David G. Iosseliani, Dmitry Kurtasov, Ilya Alexandrovich Kovalchuk, Victoria Victorovna Fomenko
Journal: Journal of the American College of Cardiology (2016)
Skindex-29 (SD-29) for health-related quality of life (HRQoL) assessment during antiEGFr therapies for colorectal cancer (CRC)
Authors: F. Meriggi, A. Rizzi, F. Andreis, L. Rota, M. Mazzocchi, B. Di Biasi, C. Codignola, A. Zaniboni
Journal: Journal of Clinical Oncology (2008)

20721 Background: Cetuximab and panitumumab have demonstrated clinical activity in CRC treatment. However, their use is associated with dermatologic reactions of varying severity. The impact on HRQoL of these toxicities is still partially unknown. SD-29 is an extensively studied HRQoL instrument in dermatological disease (Chren. Arch Dermatol 1997), consisting of 29 questions covering: burden of symptoms, functioning and emotional domains, with a five-point Likert scale (from: “never” to “all the time”, higher scores indicate worse effects on QoL). Methods: We performed an exploratory cross-sectional study aimed to test SD-29 questionnaire in 25 pts with advanced CRC experiencing at least a grade II (NCI-CTC) skin rash and treated with at least 8 weeks of cetuximab (21 pts) or panitumumab (4 pts) in combination with chemotherapy or as monotherapy (6 pts) for metastatic CRC. Results: Among the 21 evaluable pts, mean score for emotions, symptoms and functioning was 14.1, 21.3 and 15.7, respectively (published mean scale scores for healthy volunteers: 9.2, 13.8 and 3.7, respectively, Lasek. Arch Dermatol 1998). Looking at single specific items dealing with sex life interference or to be ashamed or angered or closeness with loved ones due to skin conditions, < than 10% of pts answered 4 or 5 (“often” and “all the times”). Conclusions: SD-29 seems to be an useful tool for the assessment of HRQoL during anti-EGFr inhibitors therapies. A prospective comparison or integration with EORTC QLQ-C30 is warranted. No significant financial relationships to disclose.
Global Burden of Thrombosis
Authors: Aaron M. Wendelboe, Gary E. Raskob
Journal: Circulation Research (2016)

Thromboembolic conditions were estimated to account for 1 in 4 deaths worldwide in 2010 and are the leading cause of mortality. Thromboembolic conditions are divided into arterial and venous thrombotic conditions. Ischemic heart disease and ischemic stroke comprise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise venous thromboembolism. Atrial fibrillation is a major risk factor for stroke and systemic arterial thromboembolism. Estimates of the global burden of disease were obtained from Global Burden of Disease Project reports, recent systematic reviews, and searching the published literature for recent studies reporting measures of incidence, burden, and disability-adjusted life-years. Estimates per 100 000 of the global incidence rate (IR) for each condition are ischemic heart disease, IR=1518.7; myocardial infarction, IR=139.3; ischemic stroke, IR=114.3; atrial fibrillation, IR=77.5 in males and 59.5 in females; and venous thromboembolism, IR=115 to 269. Mortality rates (MRs) for each condition are ischemic heart disease, MR=105.5; ischemic stroke, MR=42.3; atrial fibrillation, MR=1.7; and venous thromboembolism, MR=9.4 to 32.3. Global public awareness is substantially lower for pulmonary embolism (54%) and deep-vein thrombosis (44%) than heart attack (88%) and stroke (85%). Over time, the incidence and MRs of these conditions have improved in developed countries, but are increasing in developing countries. Public health efforts to measure disease burden and increase awareness of symptoms and risk factors need to improve, particularly in low- and middle-income regions to address this leading cause of morbidity and mortality.
Low emetic chemotherapy–induced nausea and vomiting: a prospective, multicenter, observational study
Authors: Toshinobu Hayashi, Mototsugu Shimokawa, Mikako Hiraike, Yoko Toriyama, Chiaki Yokota, Jun Taniguchi, Masanori Hanada, Kyouichi Tsumagari, Noriko Okubo, Yoshimichi Koutake
Journal: Annals of Oncology (2015)
Case 34-1991
Authors: J.V. Bonventre, R.B. Colvin
Journal: New England Journal of Medicine (1991)

Presentation of CaseA 51-year-old man was admitted to the hospital because of severe hypertension and increasing renal failure.There was a five-year history of mild, labile hypertension that was treated for three months with hydrochlorothiazide–triamterene four years before admission; the patient did not tolerate the medication, and it was discontinued. Six months before entry, at a routine physical examination, the blood pressure was 210/120 mm Hg. The creatinine was 140 μmol per liter (1.6 mg per 100 ml). An x-ray film of the chest was said to be "clear." Enalapril was prescribed, but control of the hypertension became increasingly . . .
Abstract 3552: Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple negative breast cancers
Authors: Alexander Beatty
Journal: Cancer Research (2015)

Abstract Identifying metabolic pathway alterations that are critical to support cancer growth is a key hurdle for developing therapeutic strategies that exploit these pathways. We have applied metabolomic and pharmacological approaches to identify targetable pathways in triple negative breast cancer (TNBC). TNBC is an aggressive and genomically heterogeneous subset of breast cancer that is resistant to existing targeted therapies. To identify dysregulated metabolic pathways in TNBC, we conducted mass spectrometry-based metabolomics of TNBC and control cells. The relative levels of 155 intracellular metabolites distinguished TNBC from non-transformed breast epithelia, and revealed two metabolic subtypes within TNBC that, unexpectedly, correlate with markers of basal-like versus non-basal-like status. Distinguishing metabolites included amino acids, lipids and the cellular redox buffer glutathione. Levels of glutathione were generally lower in TNBC cell lines compared to controls, and markedly lower in the metabolic subtype containing non-basal-like TNBC. Further, these cell lines showed enhanced sensitivity to inhibition of glutathione biosynthesis, showing a dependence on glutathione production for survival. These findings demonstrate the potential of targeting the glutathione biosynthetic pathway as a therapeutic strategy in TNBC, and suggest that existing clinical biomarkers may provide a means for stratifying TNBC tumors to identify likely responders to anti-glutathione therapy. Citation Format: Alexander Beatty. Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple negative breast cancers. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3552. doi:10.1158/1538-7445.AM2015-3552
An abnormal post-procedure chest radiograph
Authors: Abhishek Maiti, Robert F Lodato
Journal: BMJ (2016)

A 55 year old man with lymphoma was admitted to the intensive care unit with severe sepsis and hypoxic respiratory failure as a result of healthcare associated pneumonia. At admission he had altered mental status and soon afterwards developed an episode of unstable bradycardia when his mean arterial pressure dropped to 26 mm Hg, and oxygen saturation dropped to 62% on 6 L oxygen through a nasal cannula. He underwent emergent endotracheal intubation, ultrasound guided right internal jugular central venous catheter (CVC) and left radial …
TCTAP A-161 The Association of Cardiac Valve Sclerosis with Clinical Outcomes in Patients Undergoing Endovascular Revascularization for Peripheral Arterial Disease
Authors: Ji Young Park, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Sang-Ho Park, Jae Kyeong Byun, Min Shim, Eun Jin Park, Jah Yeon Choi, Jae Joong Lee, Sunki Lee, Li Hu, Cheol Ung Choi, Jin Oh Na, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2016)
Oral Amalgam Tattoo Mimicking Melanoma
Authors: Cristián Vera-Kellet, Pablo Del Barrio-Díaz
Journal: New England Journal of Medicine (2016)

A 49-year-old woman without a personal or family history of melanoma presented with an asymptomatic pigmented lesion on her tongue that was suggestive of oral melanoma. The patient reported that she had undergone a dental procedure 3 months before the appearance of the lesion.
TCTAP A-074 Hospital and Long-Term Results of Endovascular Treatment of Patients with Acute Myocardial Infarction Complicated with Primary Ventricular Fibrillation
Authors: Igor Yu. Kostyanov, Dzhamil Arif Asadov, Nino V. Tsereteli, Irina E. Chernysheva, Pavel S. Vasiliev, David G. Iosseliani
Journal: Journal of the American College of Cardiology (2016)
A single-institution validation of the AJCC staging system for stage IV melanoma
Authors: H. Neuman, A. Patel, C. Hanlon, M. S. Brady, A. C. Halpern, A. N. Houghton, D. G. Coit
Journal: Journal of Clinical Oncology (2007)

8517 Background: We sought to validate the AJCC staging system for stage IV melanoma in a contemporary, prospective, single- institution cohort and explore additional clinical factors that may influence prognosis. Methods: A prospective institutional database identified 1319 patients with stage IV melanoma. To minimize tertiary center referral bias, only patients seen prior to a stage IV diagnosis were included (n=687). Variables were dichotomized: lactate dehydrogenase (LDH) (=200, &gt;200), number of metastases (1, &gt;1), and number of involved organs (1, &gt;1). Kaplan-Meier curves were generated and Cox regression was used to identify factors independently predictive of survival. Results: Demographics are provided in the table . The median age at diagnosis of stage IV was 55 years (range 16–94) and the median disease free interval (DFI) was 12 months (0–181). The overall median survival was 10 months (5–21) with a median follow-up for survivors of 31 months (9–68); 569 deaths were observed. Cox regression analysis ( table ) identified younger age at stage IV diagnosis, a longer DFI, and a normal LDH to be predictive of improved survival. Patients with either distant skin/subcutaneous/nodal or pulmonary disease experienced prolonged survival when compared to patients with metastases to other visceral sites. Survival was improved in patients with a single metastatic site at diagnosis of stage IV. Gender, antecedent stage, and number of involved organs were not associated with outcome. Conclusions: In this single institution cohort of patients with stage IV melanoma, poorer survival in patients with non-pulmonary visceral metastases and/or abnormal LDH levels as described by the AJCC staging system was confirmed. Additionally, the number of metastases at the time of diagnosis of stage IV was the most powerful predictor of poorer survival and may be a variable to consider in future staging systems. No significant financial relationships to disclose. [Table: see text]
Gastrointestinal and Liver Issues in Heart Failure
Authors: Varun Sundaram, James C. Fang
Journal: Circulation (2016)

Heart failure affects ≈23 million people worldwide and continues to have a high mortality despite advancements in modern pharmacotherapy and device therapy. HF is a complex clinical syndrome that can result in the impairment of endocrine, hematologic, musculoskeletal, renal, respiratory, peripheral vascular, hepatic, and gastrointestinal systems. Although gastrointestinal involvement and hepatic involvement are common in HF and are associated with increased morbidity and mortality, their bidirectional association with HF progression remains poorly fathomed. The current understanding of multiple mechanisms, including proinflammatory cytokine milieu, hormonal imbalance, and anabolic/catabolic imbalance, has been used to explain the relationship between the gut and HF and has been the basis for many novel therapeutic strategies. However, the failure of these novel therapies such as anti–tumor necrosis factor-α has resulted in further complexity. In this review, we describe the involvement of the gastrointestinal and liver systems within the HF syndrome, their pathophysiological mechanisms, and their clinical consequences.
Abstract 12033: Impact of n-3 Polyunsaturated Fatty Acids on Mortality of Patients With Hospitalized Heart Failure Patients
Authors: Shunsuke Watanabe, Akiomi Yoshihisa, Yuki Kanno, Mai Takiguchi, Shunsuke Miura, Akihiko Sato, Takeshi Shimizu, Yuichi Nakamura, Hiroyuki Yamauchi, Takashi Owada, Satoshi Abe, Satoshi Suzuki, Masayoshi Oikawa, Nobuo Sakamoto, Takayoshi Yamaki, Koichi Sugimoto, Hiroyuki Kunii, Kazuhiko Nakazato, Hitoshi Suzuki, Shu-ichi Saitoh, Yasuchika Takeishi
Journal: Circulation (2015)

Background: Intake of n-3 polyunsaturated fatty acids (n-3 PUFA), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lowers risk of atherosclerotic cardiovascular events, particularly ischemic heart disease. In addition, a ratio of EPA/arachidonic acid (AA) is recently recognized as a risk marker of ischemic heart disease. In contrast, prognostic impact of the EPA, DHA and EPA/AA ratio on patients with heart failure (HF) still remains unclear. Methods and Results: Consecutive 577 patients admitted for HF were divided into 2 groups based on median levels of EPA/AA ratio: low EPA/AA (EPA/AA ≤ 0.32 mg/dl, n=291) and high EPA/AA (0.32 &lt; EPA/AA, n=286) groups. We compared laboratory data, echocardiographic findings and cardio-pulmonary exercise test results, and prospectively followed cardiac and all-cause mortality. The low EPA/AA group, as compared to the high EPA/AA group, had lower levels of EPA and DHA (EPA: 33.9 vs. 86.8 μg/ml, P&lt;0.003; DHA: 107.0 vs. 150.5 μg/ml, P&lt;0.001), and higher levels of AA and dihomosexual linolenic acid (AA: 174.0 vs. 156.5 μg/ml, P&lt;0.001; dihomosexual linolenic acid: 32.4 vs. 29.5 μg/ml, P=0.010). In contrast, body mass index, blood pressure, B-type natriuretic peptide, hemoglobin, estimated GFR, total protein, albumin, sodium, C-reactive protein, left ventricular ejection fraction, peak VO 2 and VE/VCO 2 slope were similar between the two groups. Cardiac mortality (log-rank P=0.004) and all-cause mortality (P&lt;0.001) were higher in the low EPA/AA group than in the high EPA/AA group. In the multivariable Cox proportional hazard analyses, the EPA/AA ratio was an independent predictor of cardiac mortality (HR 0.087, P=0.003) and all-cause mortality (HR 0.233, P=0.009) in HF patients. Conclusions: The EPA/AA ratio was an independent predictor of cardiac and all-cause mortality in HF patients. Thus, taking appropriate management to control EPA/AA balance may improve the prognosis of HF patients.
Case 22-1990
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Lawrence N. Shulman, Lawrence R. Zukerberg
Journal: New England Journal of Medicine (1990)

Presentation of CaseA 19-year-old woman was admitted to the hospital because of a painful mass in the right shoulder and jaundice.The patient was well until approximately nine months earlier, when she began to have intermittent pain in the right shoulder. One month before admission the pain became more severe and at times radiated into the right upper arm; at about the same time she became aware of an enlarging mass in the right shoulder that was tender when she rolled onto it in bed. Her abdominal girth began to increase, and three weeks before admission anorexia and nausea . . .
NIMG-71ROBUSTNESS AND VALIDITY OF M1 DETERMINATION BY NAVIGATED TRANSCRANIAL MAGNETIC STIMULATION (NTMS) AND FUNCTIONAL MRI AS COMPARED TO INTRAOPERATIVE DIRECT CORTICAL STIMULATION (DCS)
Authors: Carolin Weiss Lucas, Volker Neuschmelting, Charlotte Nettekoven, Ana-Maria Oros-Peusquens, Gabriele Stoffels, Christian Grefkes, Andrea Maria Faymonville, Roland Goldbrunner
Journal: Neuro-Oncology (2015)

INTRODUCTION: Imaging of the primary motor representation (M1) prior to brain tumour surgery is helpful to achieve a maximum extent of resection whilst preserving motor functions. To date, functional magnetic resonance imaging (fMRI) has been the most commonly used localizer technique for primary motor functioning. However, navigated transcranial magnetic stimulation (nTMS) gains increasing acceptance due to its high resolution and little dependence on the patients' compliance. We compared the congruency of nTMS vs. fMRI results with the gold standard method of direct cortical simulation (DCS). METHODS: 32 patients with intracerebral tumours underwent nTMS and fMRI prior to surgery. The cortical hot spots (HS) and Centres of Gravity (CoG) of M1 of the hand, the foot and the tongue representation were determined for each localizer technique and controlled by DCS. Euclidean distances (ED) between nTMS / fMRI and the respective DCS HS / CoG's were computed in 3D. Feasibility of both fMRI and nTMS were assessed in relation to the DCS results. RESULTS: Regarding the hand and the tongue representation, the CoG's of the nTMS maps were located significantly closer to the respective DCS-CoG's as compared to fMRI (hand [nTMS-DCS/ fMRI-DCS]: 9.7 ± 6.0 / 17.3 ± 9.6; p = 0.001; tongue: 9.4 ± 4.9 / 16.9 ± 5.9; p < 0.001 ). For the foot representation, a similar statistical trend was observed (12.2 ± 6.5 / 19.2 ± 12.9; p = 0.1). However, comparison of hot-spots did not reveal statistically significant differences. The feasibility of non-invasive localizer methods (fMRI: 100% / nTMS: 99%) was superior to DCS (71%). CONCLUSIONS: NTMS is a highly robust method for M1 mapping and seems to be superior to fMRI for mapping areas adjacent to brain tumours. Probably due to the limited depth of nTMS stimulation effects, nTMS is less clearly favourable for localizing the foot representation.
Abstract 1965: Bivalirudin and Proximal Endovascular Clamping for Carotid Artery Stenting
Authors: Eugenio Stabile, Luigi Salemme, Tullio Tesorio, Giovanni Sorropago, Angelo Cioppa, Gregory Popusoi, Vittorio Ambrosini, Angelo Ausania, Giovanni Della Pietra, Giampaolo Petroni, Paolo Rubino
Journal: Circulation (2006)

Background: The use of proximal endovascular clamping (PEC) led to a significant reduction of microembolization, during carotid artery stenting (CAS). This device requires a large femoral sheath. S...
P1195 : Characteristic changes in bile acids synthesis regulatory mechanisms in primary biliary cirrhosis. UDCA non-response is associated with higher expression of FGF19
Authors: E. Wunsch, M. Milkiewicz, J. Trottier, A. Kempinska-Podhorodecka, U. Wasik, E. Elias, O. Barbier, P. Milkiewicz
Journal: Journal of Hepatology (2015)
Obstacles to the Implementation of Antiemetic Guidelines
Authors: Steven M. Grunberg
Journal: Journal of the National Comprehensive Cancer Network (2009)

Although guidelines help physicians deliver high quality clinical care, they will have minimal impact unless familiarity and adherence are achieved. Although nausea and vomiting are highly feared toxicities of chemotherapy that markedly decrease patient quality of life, modifications in physician behavior and improvements in standards of care, particularly in terms of preventing delayed emesis, have been slow. Variations in format, goals, physician education, and institutional education may all affect guideline implementation and state-of-the-art care. The relationship between these factors and the scientific basis of antiemetic guidelines must be considered to achieve optimal results and compliance.
Complete resection of a 225-mm circumferential rectosigmoid intramucosal carcinoma by endoscopic submucosal dissection
Authors: Haruo Takahashi, Yoshikazu Hayashi, Keijiro Sunada, Satoshi Shinozaki, Kunihiko Oguro, Alan Lefor, Hironori Yamamoto
Journal: Endoscopy (2016)

A 58-year-old man presented with a fully circumferential, granular-type, laterally spreading tumor in the rectosigmoid ([Fig. 1 a], [Fig. 1 b]), which was diagnosed as an intramucosal cancer using magnifying endoscopy. En bloc resection was accomplished by endoscopic submucosal dissection (ESD) using the pocket-creation method [1].
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Authors: Bruno Paiva, Maria-Teresa Cedena, Noemi Puig, Paula Arana, Maria-Belen Vidriales, Lourdes Cordon, Juan Flores-Montero, Norma C. Gutierrez, María-Luisa Martín-Ramos, Joaquin Martinez-Lopez, Enrique M. Ocio, Miguel T. Hernandez, Ana-Isabel Teruel, Laura Rosiñol, María-Asunción Echeveste, Rafael Martinez, Mercedes Gironella, Albert Oriol, Carmen Cabrera, Jesus Martin, Joan Bargay, Cristina Encinas, Yolanda Gonzalez, Jacques J. M. Van Dongen, Alberto Orfao, Joan Bladé, Maria-Victoria Mateos, Juan José Lahuerta, Jesús F. San Miguel
Journal: Blood (2016)
Treatment (T) of Metastatic Colorectal Cancer (Mcrc) Patients (Pts) ≥75 Years (Y) Old in Clinical Practice: a Multicenter Analysis
Authors: R. Grande, I. Pavese, C. Natoli, F. Ciancola, D. Gemma, A. Pellegrino, C. Garufi, L. Di Lauro, D.C. Corsi, D. Signorelli, I. Sperduti, G. Cortese, E. Risi, F. Morano, D. Sergi, C. Signorelli, E.M. Ruggeri, G. Zampa, M. Russano, T. Gamucci
Journal: Annals of Oncology (2014)